

NEWS FROM INVIVO THERAPEUTICS CORPORATION

One Broadway, 14th Floor • Cambridge, MA 02142 • 617-583-1315 • www.invivotherapeutics.com

11-13-08 November ####, 2008

Contacts:

Frank Reynolds 617-583-1315
info@invivotherapeutics.com

Anita Harris 617-576-0906
anita.m.harris@harriscom.com

For Immediate Release:

WORLD RENOWNED SCIENTISTS JOIN INVIVO THERAPUETICS BOARDS

Device company developing technology to help heal traumatic spinal cord injury

Cambridge, MA, November #### InVivo Therapeutics Corporation announced today that Nobel-prize winning scientist Richard Roberts, PhD, will join its Board of Directors and that renowned spinal cord expert V. Reggie Edgerton, PhD, of the University of California, Los Angeles (UCLA) has joined the company's scientific advisory board (SAB).

InVivo Therapeutics is a medical device company focused on restoring function in individuals paralyzed by traumatic spinal cord injury. The company has advanced to its second round of nonhuman primate trials and has applied to the Food and Drug Administration for permission to enter clinical trials within a year.

"These outstanding scientists bring invaluable expertise as InVivo proceeds toward clinical trials," said Frank Reynolds, the company's founder and chief executive officer.

"Dr. Roberts, who joined InVivo's SAB in 2007, is a pre-eminent scientist with many years of experience in the business realm. Professor Edgerton is an internationally known expert whose career has focused on finding ways to help individuals paralyzed by traumatic spinal cord injury recover motor function. I am very pleased that they will be working with our growing team."

Richard Roberts Named Director at InVivo Therapeutics

Roberts is Chief Scientific Officer at New England Biolabs, Inc., a world leader in the production and supply of reagents for the life science industry. In 1993, Roberts won a Nobel Prize in Physiology or Medicine for the discovery that a given gene could be present in DNA as several, well-separated segments. The discovery of "split genes" has been of great importance to basic biological and more- medically-oriented research.

"InVivo's preliminary results look quite good," Roberts said. "I am pleased to join the company's Board of Directors because, if proved successful, this new technology could help people rather quickly and I want to contribute to its success."

Educated in England, Roberts completed postdoctoral research at Harvard University and later worked with James D. Watson, PhD, at Cold Spring Harbor Laboratory, in New York State. Roberts is known for his work in molecular and computational biology—and especially for his pioneering use of computer methods and databases for studying DNA and its component structures.

V. Reggie Edgerton joins distinguished InVivo SAB

Edgerton is Director of the Neuromuscular Research Laboratory within the Department of Physiological Science and **Director of** the Brain Research Institute at UCLA. His research has long focused on the plasticity of the spinal cord and musculature with respect to possible recovery from injury and other neuromuscular disorders. Dr. Edgerton, who received his PhD from Michigan State University, has authored more than 300 research papers and two books. He has won numerous awards—most recently, the

QUOTE from Dr. Edgerton.

InVivo Therapeutics Scientific Advisory Board

Dr. Edgerton joins a group of distinguished scientists and doctors on InVivo's SAB. The group includes: Robert Langer, ScD, Institute Professor at MIT; Richard J. Roberts, PhD, Chief Scientific Officer at New England Biolabs and a 1993 Nobel Laureate in Medicine and Physics; Eric Woodard, MD, Chief of Neurosurgery at New England Baptist Hospital in Boston; Todd J. Albert, MD, James Edwards, Professor and Chair of the Department of Orthopaedics at Jefferson Medical College and President of the Rothman Institute, in Philadelphia; Jonathan Slotkin, MD, clinical neurosurgeon and research scientist at New England Baptist Hospital; and Alexander R. Vaccar, MD, who co-directs the Delaware Valley Regional Spinal Cord Injury Center, the Spine Fellowship at Thomas Jefferson University, and Reconstructive Spine Services at the Rothman Institute, in Philadelphia.

*

Every year, more than 170 thousand people worldwide are left paralyzed by traumatic spinal cord injuries, according to US government statistics. Although it is not currently possible to repair such injuries, the InVivo team believes that by minimizing additional injury to surrounding tissue and promoting new tissue growth, it will be able to improve function in spinal cord injury patients.

*

InVivo Therapeutics Corporation is a Cambridge, MA medical device company focused on combining polymers and stem cells to restore function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of research initiated in the laboratories of Robert Langer, ScD, of the Massachusetts Institute of Technology, and Jay Vacanti, MD, of the Massachusetts General and Children's Hospitals in Boston.

###